UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC 20549



                                  FORM 10-QSB/A




[X]   Quarterly Report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

      For the quarterly period ended  August 31, 2005
                                      -----------------

[ ]   Transition Report pursuant to 13 or 15(d) of the Securities Exchange
      Act of 1934

      For the transition period                  to
                               ------------------   --------------------

      Commission File Number    333-107179
                            -----------------


                             XPENTION GENETICS, INC.
    ------------------------------------------------------------------------
       (Exact name of small Business Issuer as specified in its charter)


                               BAYVIEW CORPORATION
    ------------------------------------------------------------------------
     (Former name, former address and former fiscal year, if changed since
                                 last report)



          Nevada                                         98-0380519
---------------------------------             --------------------------------
(State or other jurisdiction of              (IRS Employer Identification No.)
 incorporation or organization)

10965 Elizabeth Drive
Conifer, CO                                               80433
----------------------------------------      --------------------------------
(Address of principal executive offices)           (Postal or Zip Code)


Issuer's telephone number, including area code:        (303) 908-4900
                                                ------------------------------

<PAGE>

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Securities  Exchange  Act of 1934  during the  preceding  12
months (or for such  shorter  period  that the issuer was  required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days [X] Yes [ ] No

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).        [_] Yes         [X] No

State the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date:  57,625,833 shares of $0.001 par value
common stock outstanding as of August 31, 2005.

Transitional Small Business Disclosure Format (Check one):   [_] Yes     [X] No


<PAGE>

                          PART I FINANCIAL INFORMATION

Item 1.  Financial Statements


                             XPENTION GENETICS, INC.
                         (An Exploration Stage Company)

                                 AUGUST 31, 2005
                                   (Unaudited)
                            (Stated in U.S. Dollars)

                                    Restated


<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                                    Consolidated Balance Sheet
                                         August 31, 2005
                                     (Unaudited and Restated)


ASSETS

<S>                                                                           <C>
Current assets
Cash and cash equivalents                                                     $            298,752
                                                                              =====================


LIABILITIES

Current liabilities
Accounts payable                                                              $              5,611
Accrued expenses                                                                            84,401
   Note payable                                                                            100,000
                                                                              ---------------------
    Total current liabilities                                                              190,012
                                                                              ---------------------


STOCKHOLDERS' (DEFICIT)

Preferred stock, $0.001 par value, 10,000,000 shares authorized,
none issued or outstanding                                                                       -
Common stock, $0.001 par value, 100,000,000 shares authorized,
 57,625,833 shares issued and outstanding                                                   57,626
Additional paid-in capital                                                                 711,474
Deferred stock compensation                                                               (276,750)
   (Deficit) accumulated during the development stage                                     (383,610)
                                                                              ---------------------
                                                                                           108,740
                                                                              ---------------------

                                                                              $            298,752
                                                                              =====================
</TABLE>



 The accompanying footnotes are an integral part of these financial statements.

                                      F-1
<PAGE>

<TABLE>
<CAPTION>

                               XPENTION GENETICS, INC.
                            (A Development Stage Company)
                        CONSOLIDATED STATEMENTS OF OPERATIONS
                       THREE MONTHS ENDED AUGUST 31, 2005 AND
                   (INCEPTION) OCTOBER 13, 2004 TO AUGUST 31, 2005
                              (Unaudited and Restated)



                                                                                                       (Inception)
                                                                        Three Month Ended            October 13, 2004
                                                                         August 31, 2005            To August 31, 2005
                                                                      ----------------------    ---------------------------
<S>                                                                   <C>                       <C>
Revenues                                                              $                   -     $                        -
                                                                      ----------------------    ---------------------------

Expenses
    Research and development                                                         78,760                         78,760
    General and administrative non cash stock compensation                           92,250                         92,250
 General and administrative                                                          54,600                        208,199
                                                                      ----------------------    ---------------------------
                                                                                    225,610                        379,209
                                                                      ----------------------    ---------------------------

Operating (loss)                                                                   (225,610)                      (379,209)
                                                                      ----------------------    ---------------------------

Other income (expense)
Interest expense                                                                     (1,250)                        (4,401)
                                                                      ----------------------    ---------------------------

Net (loss)                                                            $            (226,860)     $                (383,610)
                                                                      ======================    ===========================


Basic and diluted:
  (Loss) per share                                                    $               (0.00)    $                    (0.01)
                                                                      ======================    ===========================

  Weighted average shares outstanding                                            57,434,529                     57,011,651
                                                                      ======================    ===========================

         The accompanying footnotes are an integral part of these financial statements.

                                              F-2
</TABLE>

<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                              CONSOLIDATED STATEMENTS OF CASH FLOWS
                             THREE MONTHS ENDED AUGUST 31, 2005, AND
                         (INCEPTION) OCTOBER 13, 2004 TO AUGUST 31, 2005
                                    (Unaudited and Restated)

                                                                                                     (Inception)
                                                              Three Month Ended                   October 13, 2004
                                                               August 31, 2005                   To August 31, 2005
                                                        ------------------------------    ----------------------------------
<S>                                                     <C>                               <C>
Cash Flows From Operating Activities
Net (loss)                                              $                    (226,860)    $                        (383,610)
Adjustments to reconcile net (loss) to net cash (used
      in) operating activities
      Stock compensation expense                                               92,250                                92,250
      Accounts payable and accrued liabilities                                 17,940                                90,012
                                                        ------------------------------    ----------------------------------
Cash flows (used in) operating activities                                    (116,670)                             (201,348)
                                                        ------------------------------    ----------------------------------


Cash Flows From Investing Activities
                                                        ------------------------------    ----------------------------------
Cash flows provided by (used in) investing activities                               -                                     -
                                                        ------------------------------    ----------------------------------


Cash Flows From Financing Activities
   Proceeds from note payable                                                       -                               100,000
   Proceeds from issuance of common stock                                     400,000                               400,100
                                                        ------------------------------    ----------------------------------
Cash flows provided by financing activities                                   400,000                               500,100
                                                        ------------------------------    ----------------------------------

Increase in cash                                                              283,330                               298,752

Cash, beginning of period                                                      15,422                                     -
                                                        ------------------------------    ----------------------------------

Cash, end of period                                     $                     298,752     $                         298,752
                                                        ==============================    ==================================


Supplemental cash flow information
  Income taxes paid                                     $                           -     $                               -
                                                        ==============================    ==================================
  Interest expense paid                                 $                           -     $                               -
                                                        ==============================    ==================================


         The accompanying footnotes are an integral part of these financial statements.

                                              F-3
</TABLE>

<PAGE>

<TABLE>
<CAPTION>

                                             XPENTION GENETICS, INC.
                                          (A Development Stage Company)
                            CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
                                 INCEPTION (OCTOBER 13, 2004) TO August 31, 2005

                                                                                                  (Deficit)
                                                                                    Deferred     Accumulated
                                                Common Stock         Additional       Stock       During the
                                              Shares      Amount  Paid in Capital Compensation  Development Stage   Total
                                           -------------------------------------------------------------------------------
<S>                                        <C>            <C>          <C>            <C>          <C>          <C>
Inception (October 13, 2004)                          -        $ -           $ -             $ -          $ -         $ -

Stock issued for cash                        14,300,000        100             -               -            -         100

Recapitalization                             42,542,500          -             -               -            -           -

Net (loss)                                            -          -             -               -     (156,750)   (156,750)
                                           -------------------------------------------------------------------------------

Balance, May 31, 2005                        56,842,500        100             -               -     (156,750)   (156,650)

June 15, 2005 Private placement                 333,333        333       399,667               -            -     400,000

June 28, 2005 stock issued for research &
    development                                 450,000        450       368,550               -            -     369,000

Deferred stock compensation                           -          -             -        (276,750)           -    (276,750)

Reclassification                                      -     56,743       (56,743)              -            -           -

Net (loss)                                            -          -             -               -     (226,860)   (226,860)

                                           -------------------------------------------------------------------------------
Balance August 31, 2005                      57,625,833   $ 57,626     $ 711,474      $ (276,750)  $ (383,610)  $ 108,740
                                           ===============================================================================


         The accompanying footnotes are an integral part of these financial statements.
</TABLE>

                                              F-4


<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                 August 31, 2005
                            (Unaudited and Restated)


Financial Statements

The accompanying unaudited financial statements of Xpention Genetics,  Inc. have
been prepared in accordance with generally  accepted  accounting  principles for
interim financial  information and with the instructions to Form 10-QSB and Rule
10-01 of  Regulation  S-X.  The  financial  statements  reflect all  adjustments
consisting of normal recurring adjustments, which, in the opinion of management,
are  necessary  for a fair  presentation  of the results for the periods  shown.
Accordingly,  they do not include all of the information and footnotes  required
by generally accepted accounting principles for complete financial statements.


These  financial  statements  should  be read in  conjunction  with the  audited
financial  statements and footnotes  included  thereto for the fiscal year ended
May 31, 2005, for Xpention  Genetics,  Inc. on Form 10KSB, as amended,  as filed
with the Securities and Exchange Commission.


The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
that effect the reported  amounts of revenues and expenses  during the reporting
period. Actual results could differ from those estimates.

Organization


Xpention Genetics,  Inc. (the Company) was incorporated in the State of Colorado
on October 13, 2004, and has been in the development  stage since its inception.
In March 2005, the Company  entered the  biotechnology  industry to develop both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human cancers.  In March 2005 the Company changed its name to Xpention Genetics,
Inc. The Company has been in the  development  stage since its formation and has
not yet  realized  any  revenues  from its planned  operations.  The Company has
chosen May 31 as its fiscal year-end and.


During March 2005 Bayview  issued  14,300,000  shares of its common stock to the
shareholders  of the  Xpention,  Inc.  in  exchange  for all of the  issued  and
outstanding  common  shares of  Xpention  pursuant to an  Agreement  and Plan of
Reorganization.  In addition,  Concurrent  with the exchange of shares,  Bayview
changed its name to Xpention Genetics, Inc.

                                      F-5


<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                 August 31, 2005
                            (Unaudited and Restated)

This   acquisition  of  Xpention,   the  accounting   acquirer,   by  Bayview  a
non-operating  entity,  is considered in substance a capital  transaction by the
issuance of  14,300,000  shares of common stock by Bayview for all of the issued
and  outstanding  common  shares of  Xpention,  and will be  accounted  for as a
reverse  acquisition,  and no  goodwill  or  other  intangible  assets  will  be
recorded.  On this basis, the historical financial statements as of and prior to
the acquisition date will represent the operations of Xpention.

Net (Loss) Per Common Share

The Company  follows SFAS 128,  "Earnings Per Share".  Basic earnings (loss) per
common share  calculations  are  determined by dividing net income (loss) by the
weighted average number of shares of common stock  outstanding  during the year.
Diluted earnings (loss) per common share calculations are determined by dividing
net income (loss) by the weighted  average  number of common shares and dilutive
common  share  equivalents  outstanding.   During  the  periods  when  they  are
anti-dilutive,  common  stock  equivalents,  if any, are not  considered  in the
computation.


NOTE 2. STOCKHOLDERS' EQUITY


In June 2005,  the Company  issued  333,333  shares of common  stock for cash of
$400,000, or $1.20 per share.

In June 2005,  the  Company  issued  450,000  shares of common  stock  valued at
$369,000,  or $ .82 per share in exchange for research and development  costs to
be incurred over the next 12 months. The shares were valued at their fair market
value on the date it was agreed they would be issued.  During the period $78,760
has been chared to operations as research and  development and $276,570 has been
recorded as deferred compensation at August 31, 2005.



NOTE 3. COMMITMENTS

On July 21, 2005,  the Company  entered into a Research  Agreement with Colorado
State  University for research  activities in connection with the development of
the p65  immunological  test for canines in which CSU will provide  canine blood
and tissue  specimens for use in clinical  trials.  The agreement  terminates on
July 1, 2006 and requires payments to CSU totaling $17,520.

                                      F-6

<PAGE>

                             Xpention Genetics, Inc.
                          (A Development Stage Company)
                   Notes to Consolidated Financial Statements
                                 August 31, 2005
                            (Unaudited and Restated)

NOTE 4. CORRECTION OF AN ERROR

In March 2006,  the Company  determined  that the  Bayview/Xpention  transaction
should be treated as a recapitalization rather than as a purchase, the financial
statements  and  footnotes  have been  restated  to  reflect a  decrease  in the
inception to date net loss of $86,117 or $0.00 per share.










                                      F-7


<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation

FORWARD LOOKING STATEMENTS

This quarterly report contains forward-looking statements that involve risks and
uncertainties.  We use words such as anticipate,  believe, plan, expect, future,
intend and similar expressions to identify such forward-looking  statements. You
should not place too much  reliance  on these  forward-looking  statements.  Our
actual results are likely to differ  materially from those  anticipated in these
forward-looking  statements  for many  reasons,  including the risks faced by us
described in this Risk Factors section and elsewhere in this annual report.

Plan of Operation

The Company, through its wholly-owned subsidiary,  holds the exclusive worldwide
license for  patented  technology  for the  detection of cancer based on a tumor
marker known as p65 which has been  demonstrated  to have elevated levels in the
blood of canine and human  cancer  conditions.  p65 is  believed to be a protein
required in the early  development  of numerous  cancers and appears  from early
research  to provide a strong  indication  of tumor  growth in both  canines and
humans.  It also appears to have a direct  correlation to tumor size/mass making
it a promising  marker for both early  detection of malignant tumor formation as
well as a useful tool for  monitoring  therapy  and  remission.  Initially,  the
Company plans to develop an immunological  test as well as a molecular assay for
detection  of  cancer  in  canines.  The  Company  also  plans to  develop  both
immunological  and  molecular  tests for  detection of human  cancers as well as
therapeutic treatments and vaccines.

During the interim  period  ended  August 31, 2005,  the Company  continued  its
research  activities  for the  development  of an  immunological  canine  cancer
detection  test as well as a  molecular  assay for  detection  of cancer in both
canines and humans,  all of which are being conducted by third parties on behalf
of the company. In July 2005, the Company entered into a Research Agreement with
Colorado State University in which CSU will provide blood and tissue samples for
use in clinical  trials to be conducted in connection  with  development  of the
immunological  canine  cancer  detection  test.  The Company  also  continues to
evaluate various options for  commercialization of its products;  however, it is
not   anticipated   that  the  Company   will   generate   any   revenues   from
commercialization  of its products  during FY 2006. The Company  anticipates the
trend of operating losses will continue.

Results of Operations for the Period Ending August 31, 2005


The Company  did not earn any  revenues  during the  three-month  period  ending
August 31, 2005.  The Company  incurred  expenses  totaling  $225,610  including
research  and  development  expenses  of $ 78,760,  administrative  expenses  of
$54,600 and stock compensation (non-cash) of $92,250. The Company issued 333,333
shares of stock at a price of $1.20 per share in June 2005  generating  $400,000
in cash,  the  proceeds  of which were used to cover  research  and  development
expenses  as  well  as  administrative  expenses  of  the  Company.

Since  inception,  the Company has not  generated  any revenues and has incurred
expenses  totaling  $379,209 plus interest  expense of ($4,401) for a total loss
since inception of $383,610.


The Company had $298,752 in cash on hand at August 31, 2005 and accounts payable
and accrued liabilities  totaling $90,012 and note payable of $100,000 at August
31, 2005.


Item 3.  Controls and Procedures

Evalution of Disclosure Controls

Management evaluated the effectiveness of the disclosure controls and procedures
as of August 31, 2005.  This  evaluation  was  conducted by the chief  executive
officer and principal accounting officer.

<PAGE>

Disclosure  controls  are  controls  and other  procedures  that are designed to
ensure that  information  that is  required  to  disclose  in the reports  filed
pursuant  to  the  Securities  Exchange  Act of  1934  is  recorded,  processed,
summarized and reported.

Limitations on the Effective of Controls

Management does not expect that the disclosure controls or the internal controls
over financial  reporting will prevent all error and fraud. A control system, no
matter how well  conceived and  operated,  can provide only  reasonable,  but no
absolute,  assurance that the  objectives of a control system are met.  Further,
any control  system  reflects  limitations  on resources,  and the benefits of a
control system must be considered  relative to its costs. These limitations also
include the realities that judgments in  decision-making  can be faulty and that
breakdowns can occur because of simple error or mistake. Additionally,  controls
can be circumvented by the individual acts of some persons,  by collusion of two
or more people or by  management  override  of a control.  A design of a control
system is also based upon certain assumptions about potential future conditions;
over time,  controls may become inadequate because of changes in conditions,  or
the degree of  compliance  with the  policies  or  procedures  may  deteriorate.
Because  of  the  inherent  limitations  in  a  cost-effective  control  system,
misstatements due to error or fraud may occur and may not be detected.

Conclusions

Based upon his  evaluation  of the  controls,  the chief  executive  officer and
principal  accounting  officer has concluded  that,  subject to the  limitations
noted  above,  the  disclosure  controls are  effective in providing  reasonable
assurance  that  material  information  relating to the Company is made known to
management  on a timely  basis  during the  period  when the  reports  are being
prepared.  There were no changes in the internal  controls that occurred  during
the  quarter  covered  by this  report  that have  materially  affected,  or are
reasonably likely to materially affect the internal controls.


                           PART II- OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is not a party to any pending legal proceeding.  Current  management
is not aware of any threatened litigation, claims or assessments.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The Company did not issue any  securities  during the quarter  ended  August 31,
2005.


Item 3. Defaults Upon Senior Securities

         None.

<PAGE>

Item 4. Submission of Matters to a Vote of Security Holders

         None.


Item 5. Other Information

         None.


Item 6. Exhibits and Reports on Form 8-K

        A.  Exhibits

            31 Certification  pursuant  to 18 U.S.C.  Section  1350,  as adopted
               pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

            32 Certification  pursuant  to 18 U.S.C.  Section  1350,  as adopted
               pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        B.  Reports on Form 8-K

            1.  Form 8-K filed on June 20, 2005

            2.  Form 8-K filed on August 3, 2005




<PAGE>

                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Dated:  April 19, 2006

                                        Xpention Genetics, Inc.

                                        /s/ David Kittrell
                                        ------------------------------
                                        David Kittrell, President